ANK-700 is under clinical development by Anokion and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS). According to GlobalData, Phase I drugs for Relapsing Remitting Multiple Sclerosis (RRMS) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ANK-700’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANK-700 overview
ANK-700 is under development for the treatment of relapsing remitting multiple sclerosis (rrms). The drug candidate is developed based on antigen-specific immune tolerance technology. It is administered through intravenous route.
Anokion overview
Anokion is engaged in identification and development of various therapies, vaccines and drugs for improving the treatment and outcomes of autoimmune disease across various patients. The company is headquartered in Ecublens, Switzerland.
For a complete picture of ANK-700’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
